Zanamivir Patent Expiration

Zanamivir is Used for preventing influenza. It was first introduced by Glaxosmithkline in its drug Relenza on Jul 26, 1999.

Zanamivir Patents

Given below is the list of patents protecting Zanamivir, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in	Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Drug Owner
Relenza	US6294572	Crystalline N-acetyl neuraminic acid derivatives and process for their preparation	Dec 15, 2014 (Expired)	Glaxosmithkline
Relenza	US5648379	Derivatives and analogues of 2-deoxy-2,3-didehydro-n-acetyl neuraminic acid and their use as antiviral agents	Jul 15, 2014 (Expired)	Glaxosmithkline
Relenza	US5360817	Derivatives and analogues of 2-deoxy-2,3-didehydro-N-acetyl neuraminic acid and their use as antiviral agents	Jul 26, 2013 (Expired)	Glaxosmithkline

Drugs Generating Over $1 Billion in Annual Revenue

Explore the top-performing drugs that dominate the pharmaceutical industry

View List

NCE-1 Patent Expiry in the Next 1 Year

Identify opportunities as new chemical entity (NCE-1) patents approach expiry

View List

Recently Granted Patents in EP

Find the opportunity to file Oppositions

View List